| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Laminar polysaccharide (100-800 µg/mL; 24 hours) does not cause any cytotoxicity to human melanoma cells SK-MEL-28 or normal epidermal cells JB6 Cl41. After 24 hours of treatment, the inhibition percentage of viable cell numbers is less than 15% at concentrations as high as 800. The last µg/mL [1]. After 24 and 48 hours of treatment, laminarin (200 µg/mL; 24-72 hours) did not decrease the development of SK-MEL-28 cells; however, after 72 hours of treatment, cell proliferation was reduced by 36%[1]. The phosphorylation of c-Raf (Ser259), ERK1/2 (Tyr202/Tyr204), and MEK1/2 (Ser 221) kinases, as well as total kinases examined protein expression levels, were not affected by low quantities of laminarin (25–50 µg/mL; 24 hours). On the other hand, at 50 µg/mL, p-MEK and p-ERK1/2 will decrease[1].
|
|---|---|
| ln Vivo |
When compared to mice treated with PBS, OVA, and laminarin alone, the combination of laminarin (iv; 12.5, 25, and 50 mg/kg; 21 days) with OVA (50 μg) dramatically decreased tumor mass [3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: JB6 Cl41 and SK-MEL-28 Cell Tested Concentrations: 100, 200, 400 and 800 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: No cytotoxicity to normal epidermal cells JB6 Cl41 and human melanoma Cells SK-MEL-28. Cell proliferation assay[1] Cell Types: SK-MEL-28 Cell Tested Concentrations: 200 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: diminished cell proliferation at 72 hrs (hours). Western Blot Analysis[1] Cell Types: SK-MEL-28 Cell Tested Concentrations: 25 µg/mL; 50 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of phosphorylation of c-Raf, MEK1/2 and ERK1/2 kinases. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice were injected subcutaneously (sc) (sc) with B16-OVA cells [3] Doses: 12.5, 25 and 50 mg/kg; 21-day
Route of Administration: intravenous (iv) (iv)injection Experimental Results: Prevent B16-OVA tumors by inducing Ag-specific immune responses grow. |
| References |
|
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.43
|
| Exact Mass |
504.169
|
| CAS # |
9008-22-4
|
| PubChem CID |
439306
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
902.8±65.0 °C at 760 mmHg
|
| Flash Point |
499.8±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.673
|
| LogP |
-6.08
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OC2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O
|
| InChi Key |
DBTMGCOVALSLOR-VPNXCSTESA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16?,17?,18?/m1/s1
|
| Chemical Name |
(3R,4S,5R,6R)-4-[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol
|
| Synonyms |
beta-1,3-Glucan; Iodus 40; Laminaran
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~16.67 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9122 mL | 19.8244 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9649 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
